Opinion
Video
Overcoming Challenges in NSCLC Management From a Pharmacist’s Perspective
Author(s):
A panelist discusses how non–small cell lung cancer presents significant treatment challenges due to its prevalence, high mortality rate, poor 5-year survival outcomes, and the difficulty of managing patients with advanced disease who often have poor performance status and multiple metastases, emphasizing the importance of pharmacist involvement for proper dosing, growth factor support, and comprehensive patient education about chemotherapy.
Non–Small Cell Lung Cancer Treatment Challenges: Key Points for Physicians
Non–small cell lung cancer (NSCLC) presents significant treatment challenges, particularly in subsequent lines of therapy. Here is a concise summary of the key challenges and potential approaches to address them:
Current Challenges
- NSCLC is one of the most prevalent types of lung cancer with high morbidity and mortality
- Despite improvements in 5-year overall survival rates due to immunotherapy and targeted therapy, limited subsequent-line options remain problematic
- Patients requiring subsequent line therapy often present with:
- Poor performance status
- Multiple metastatic sites
- Difficulty tolerating aggressive treatment regimens
Recommendations for Management
- Pharmacist involvement is crucial to:
- Ensure appropriate dosing
- Implement proper growth factor support when indicated
- Provide comprehensive patient education
- Patient education and supportive care are essential, particularly for chemotherapy-naive patients who face significant lifestyle adjustments
- A multidisciplinary approach focusing on both treatment optimization and supportive care appears to be key in managing these complex cases
